Emtora Biosciences is a leading biotechnology company focused on developing innovative solutions to combat rare genetic diseases and cancer. Our flagship product, eRapa™, is a groundbreaking formulation of rapamycin designed to suppress the onset and recurrence of cancer. With our cutting-edge technology and pipeline of potential treatments, we are dedicated to advancing patient care and improving outcomes.

eRapa™ holds great promise in the field of cancer prevention and aging-related diseases. It not only extends life by delaying the onset of aging-related conditions, but it also has the potential to postpone the effects of normal aging. Our research encompasses a range of early-stage cancers and precancerous conditions, including non-muscle invasive bladder cancer, low-grade prostate cancer, and Familial Adenomatous Polyposis (FAP), a rare genetic disease that leads to colon cancer.

At Emtora Biosciences, we are committed to making a real difference in the lives of patients. Contact us today to learn more about our groundbreaking research and the potential of eRapa™. Together, we can fight against these debilitating diseases and bring hope to those in need